Breast Cancer Study on Atorvastatin for Cardiotoxicity Prevention Receives $4.4 Million Funding

Breast Cancer Study on Atorvastatin for Cardiotoxicity Prevention Receives $4.4 Million Funding

heart attackCardiotoxicity is a common concern in cancer patients receiving chemotherapeutic agents, as it can lead to serious cardiovascular complications such as heart failure, myocardial ischemia, hypertension, thromboembolism, and arrhythmias. These conditions can greatly affect a patient's prognosis and survival, and pose an even greater threat to aging cancer patients.

To bolster research efforts on preventing cardiotoxic effects of cancer treatment, the National Heart, Lung and Blood Institute (NHLBI) and National Cancer Institute (NCI) granted the Wake Forest Baptist Medical Center a total of $4.4 million worth of funding for a clinical trial on the efficacy of a statin medication for patients with breast cancer. The NHLBI donated $3 million, while the NCI contributed $1.4 million.

Lead author of the study, Dr. Gregory Hundley, who is also a professor at Wake Forest Baptist, said that while the newer cancer treatments have gotten more effective, many of them can cause adverse effects. Chemotherapeutic agents that contain

Subscribe or to access all post and page content.